Ovarian cancer and antiangiogenic therapy: Caveat emptor

Journal of Clinical Oncology

Volumn 32, Issue 30, 2014, Pages 3353-3356

  Oliver, Kate E ^a   McGuire, William P ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR; PACLITAXEL; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; TOPOTECAN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CHEMOSENSITIVITY; DISEASE COURSE; ENDOTHELIUM CELL; GOLD STANDARD; HISTOLOGY; HUMAN; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECEPTOR BINDING; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; FEMALE; OVARIAN NEOPLASMS;

ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PYRIMIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SULFONAMIDES;

EID: 84908355651     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.4574     Document Type: Article

References (22)

1. Coleman RL, Monk BJ, Sood AK, et al: Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10:211-224, 2013
2. Bookman MA, Brady MF, McGuire WP, et al: Evaluation of new platinumbased treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419-1425, 2009
3. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
4. Ferrara N, Hillan KJ, Gerber HP, et al: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400, 2004
5. Frumovitz M, Sood AK: Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol 104:768-778, 2007
6. Hall M, Gourley C, McNeish I, et al: Targeted anti-vascular therapies for ovarian cancer: Current evidence. Br J Cancer 108:250-258, 2013
7. Eskander RN, Tewari KS: Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma: Mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol 132:496-505, 2014
8. Monk BJ, Dalton H, Farley JH, et al: Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol Hematol 86:161-175, 2013
9. Friedlander M, Hancock KC, Rischin D, et al: A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119:32-37, 2010
10. Burger RA, Brady MF, Bookman MA, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473-2483, 2011
11. Perren TJ, Swart AM, Pfisterer J, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484-2496, 2011
12. Oza AM, Perren TJ, Swart AM, et al: ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. European Cancer Congress 2013 (ECCO 17, ESMO 38, ESTRO 32), Amsterdam, the Netherlands, September 27-October 1, 2013 (abstr 6)
13. Aghajanian C, Blank SV, Goff BA, et al: OCEANS: A randomized, doubleblind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039-2045, 2012
14. Pujade-Lauraine E, Hilpert F, Weber B, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302-1308, 2014
15. du Bois A, Floquet A, Kim J-W, et al: Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 32:3374-3382, 2014
16. GlaxoSmithKline: Regulatory update: Votrient (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU. London, United Kingdom, 2014. http://www.gsk.com/media/press-releases/2014/regulatoryupdate-votrient-pazopanib-as-maintenance-therapy-.html
17. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
18. Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699-708, 2000
19. Takano S, Kimu H, Tsuda K, et al: Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab. Acta Neurochir Suppl 118:185-189, 2013
20. Ocana A, Amir E, Vera F, et al: Addition of bevacizumab to chemotherapy for treatment of solid tumors: Similar results but different conclusions. J Clin Oncol 29:254-256, 2011
21. Herzog TJ, Armstrong DK, Brady MF, et al: Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol 132:8-17, 2014
22. Gourley C, McCavigan A, Perren T, et al: Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol 32:351s, 2014 (suppl; abstr 5502)